Chemotherapy options in elderly and frail patients with metastatic colorectal cancer

Annals of Gastroenterology

Volumn 25, Issue 3, 2012, Pages 274-275

  Saif, Muhammad Wasif ^a  

^a New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGED; AGING; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; ELDERLY CARE; FRAIL ELDERLY; GERIATRIC ASSESSMENT; HUMAN; METASTASIS; PATIENT PREFERENCE; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 84863479369     PISSN: 11087471     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Saif MW, Lichtman SM. Chemotherapy options and outcomes in older adult patients with colorectal cancer. Crit Rev Oncol Hematol 2009;72:155-169.
2. Seymour MT, Thompson LC, Wasan HS, et al. FOCUS2 Investigators; National Cancer Research Institute Colorectal Cancer Clinical Studies Group. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011;377:1749-1759.
3. Yancik R. Population aging and cancer: a cross-national concern. Cancer 2005;11:437-441.
4. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005;11:449-460.
5. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J 2005;11:461-473.
6. Lichtman SM, Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 2000;7:548-556.
7. Wedding U, Honecker F, Bokemeyer C, et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 2007;14:44-56.
8. Ferrucci L, Guralnik JM, Cavazzini C, et al. The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol 2003;46:127-137.
9. Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized controlled trial. Lancet 2007;370:135-142.
10. Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial. Lancet 2007;370:143-152.
11. Ducreux M, Malka D, Mendiboure J, et al; for the Fédération Francophone de Cancérologie Digestive (FFCD) 2000-05 Collaborative Group. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomized, phase 3 trial. Lancet Oncol 2011;12:1032-1044.